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Fewer than 5% of patients with distant visceral 
metastases from cutaneous melanoma survive 12 
months and there are no effective drug treatments [1]. 
The early molecular steps in formation of melanoma are 
therefore the subjects of intense scrutiny. Cutaneous 
melanoma arises from benign melanocytic lesions 
(benign naevi) or de novo from melanocytes of the skin 
[2]. Mutations activating the N-RAS or B-RAF kinase 
components of the mitogen-activated protein kinase 
(MAPK) pathway are found in approximately 15% and 








































































the  activation  of  both  the  p16
INK4a/pRb  and  p53/p21

















than 89% of B-RAF mutations in melanoma alter a 
single amino acid (V600E and V600K), whereas highly 
recurrent mutations affecting Gly-12, Ala-18 and Gln-
61 account for approximately 12%, 5% and 70% of 
melanoma-associated N-RAS mutations, respectively 
[6]. The B-RAF
V600E and N-RAS
Q61K mutations are also 
found in up to 80% and 55% of benign naevi, 
respectively [7, 8] and benign naevi display several 
markers of senescence, including positive senescence-
associated ß-galactosidase (SA-ß-Gal) activity and 
p16
INK4a expression [9, 10]. Although the presence of 
senescent cells in human benign naevi remains 
controversial [11], accumulating evidence suggests that 
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to tumour formation (Reviewed in [12]). Defining the 
relationship between oncogene activation, melanocyte 
senescence and escape from senescence remains an 
essential step in understanding melanomagenesis. For 
this reason we have sought to dissect the regulation of 
senescence in melanocytes. 
 
The senescence program is established and maintained 
by the p53 and p16
INK4a/retinoblastoma (pRb) tumour 
suppressor pathways. p53 engages a formidable 
proliferative arrest primarily in response to DNA-
damage checkpoint signals triggered by telomere dys-
function and activated oncogenes [13-16]. For instance, 
the stable knockdown of p53-regulators (including 
ataxia telangiectasia mutated (ATM) and checkpoint-2 
(CHK2) kinases) or p53 itself overcame RAS-induced 
sensecence in BJ human foreskin fibroblasts [15] (Table 
1). Similarly, inactivation of the upstream p53 activator, 
ARF (p19ARF in mouse and p14ARF in human), 
overcame oncogene-induced senescence in mouse 
embryo fibroblasts (MEFs) [17, 18], and loss of p21
Waf1, 
a CDK inhibitor, activator of pRb and critical down-
stream target of p53 transactivation, caused cells to 
bypass telomere-dependent replicative and oncogene-
induced senescence in normal human fibroblasts and 
MEFs, respectively (Table 1) [19-21]. 
 
Although inactivation of the p53 pathway can reverse 
the senescence in some cells, there is an emerging 
consensus that it fails to do so in cells with an activated 
p16
INK4a/pRb pathway [14, 22, 23]. Active, hypo-
phosphorylated pRb interacts with E2F transcription 
factors and facilitates chromosome condensation at E2F 
target promoters. The reorganization of chromatin leads 
to the formation of senescence associated hetero-
chromatin foci (SAHF) and the stable repression of E2F 
target genes that are involved in the irreversible cell 
cycle arrest associated with senescence [24]. Each 
SAHF contains portions of a single condensed chromo-
some, which is enriched for common markers of 
heterochromatin, including HP1γ, histone H3 
methylated at lysine 9 (H3K9Me) and the non-histone 
chromatin protein, HMGA2 (reviewed in [25]) 
 
p16
INK4a is a positive regulator of pRb, via cyclin 
dependent kinase inhibition, and is crucial in generating 
SAHF [24]. Not surprisingly, p16
INK4a also acts as a 
tumour suppressor and is frequently inactivated in 
established human tumours. Inherited inactivating 
mutations in p16
INK4a are associated with melanoma 
susceptibility in melanoma-dense kindreds [26]. In fact, 
p16
INK4a-deficient human melanocytes, derived from 
melanoma affected individuals, show an extended 
lifespan and are immortalized by ectopic expression of 
telomerase reverse transcriptase, whereas normal 
melanocytes display neither of these features [27, 28]. 
Furthermore, replicative and oncogene-induced 
senescence are accompanied by accumulation of 
p16
INK4a in primary human cells [29-31] and ectopically 
expressed p16
INK4a initiates a senescence program 
characterized by cell cycle arrest, senescence-associated 
changes in cell morphology, increased SA-ß-Gal 
activity and the appearance of SAHF [32, 33]. 
 
The senescent states induced by the p53 and pRb 
pathways may be distinct and whether cells engage one 
or the other pathway appears to reflect the type of stress 
signal, the tissue and species of origin.  The relative 
contribution of the p53 and p16
INK4a/pRb pathways in 
melanocyte senescence remains unclear, and recent data 
suggest the possibility of p53- and pRb-independent 
senescence pathways in these cells. For instance, N-
RAS induced melanocyte senescence was associated 
with the activation of the p16
INK4a/pRb and p53 path-
ways, but did not require expression of p16
INK4a or 
p14ARF [34].  Similarly, neither p53 nor p16
INK4a were 
required for H-RAS induced senescence in human 
melanocytes. Instead, H-RAS-driven senescence was 
mediated by the endoplasmic reticulum-associated 
unfolded protein response [35]. In another report, 
senescence induced by B-RAF
V600E or N-RAS
Q61R did 
not depend on p16
INK4a or p53 but could be partially 
overcome by expression of the oncogenic transcription 
factor c-MYC [36]. In contrast, p53 was found to be one 
of 17 genes (also included IGFBP7) required for 
BRAF
V600E-mediated senescence of human melanocytes 
and p53 was also required for the induction of p16
INK4a 
following B-RAF
V600E expression [37] (Table 1). 
 
In this study we systematically assessed the relative 
importance of the tumour suppressor proteins p53, 
p21
Waf1,
  pRb and p16
INK4a in mediating oncogene-
induced senescence in human melanocytes. We confirm 
that N-RAS
Q61K induced senescence in melanocytes is 
associated with DNA damage, a potent DNA damage 
response and the activation of both the p16
INK4a/Rb and 
p53/p21
Waf1 tumour suppressor pathways. In melano-
cytes, the pRb pathway was the dominant effector of 
senescence, as its specific inactivation delayed the onset 
of senescence and weakened oncogene-induced pro-
liferative arrest, as shown by the reduced formation of 
SAHF. Although p53-deficient melanocytes underwent 
a senescence response that was indistinguishable from 
that seen in wild-type melanocytes, the p53 pathway did 
contribute to the senescence program. In particular, the 
p53 pathway initiated a delayed arrest in pRb-deficient 
melanocytes, whereas melanocytes lacking both p53 
and pRb continued to proliferate in response to 
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INK4a [34] are not required for N-RAS induced 
senescence, both can activate pRb and promote sense-
cence but only p16




















































and the formation of SAHF. These data help to explain 
the observation that whereas p16
INK4a mutations are com-
mon in human cancer, p21



















































   Human Cells  Mouse Cells 
   IMR90 Lung Fibroblasts









response          
 
     
 1. ATM 
Required[16]/Not 
required[61]  Required [15, 16]  Not studied  Not studied  Not studied 
 2. Chk2  Not studied  Required [15]  Not studied  Not studied  Not studied 
 3. p53 
Partial
3[62]/ 
Not required [24, 29, 61, 63] 
Required [15, 64]/ 
Partial
3 [62] Not  studied 
Required [37]/ 
Not required [35, 36]  Required [29] 
 4. ARF  Not required [65]  Not required [64]  Not required [66]  Not required [34]  Required [18, 67] 
 5. p21
Waf1  Not required [63]  Not studied  Not studied  Not required (this work)  Not required [21] 
pRb pathway                
 1. pRb 
Partial
3,4 [24, 62]/  Partial
4[62]/ 
Not required[64]  Not studied  Partial
3,4 (this work) 
Not required [45, 
68]  Not Required [61] 
 2. p107  Not studied  Not studied  Not studied  Not studied  Not required [68] 
 3. pRb and p107  Not studied  Not studied  Not studied  Not studied  Required [68] 
 4. p107 and p130  Not studied  Not studied  Not studied  Not studied  Not required [45] 
 5. pRb, p107 and 






Not required [64] 
Required[39, 66, 69, 70]/ 
Not required [71] 
Partial
4[34]/ 
Not required [35, 36]  Not required [16] 
Required [29]/ 
Not required [18] 
p53 and pRb  Required [61, 62]  Required [62]  Not studied  Required (this work)  Required [29] 
p53- and pRb-
independent                
 1. ER-stress response  Not studied  Not studied  Not studied  Required [35]  Not studied 
 2. IL-6  Required [72]  Not studied  Not studied  Not studied
6 [72] Not  studied 
 3. IGFBP7  Not studied  Not studied  Not studied  Required [37]  Not studied 
 4. C-MYC  Not studied  Not studied  Not studied  Partial
5 [36] Not  studied 
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The response of primary human melanocytes to the 
oncogenic, melanoma-associated N-RAS
Q61K mutant was 
evaluated by stably transducing N-RAS
Q61K into human 
epidermal melanocytes. Accumulation of N-RAS
Q61K 
was detected three days post-transduction and the impact 
of N-RAS on melanocyte proliferation was monitored 
over 15 days. As expected, 15 days post-transduction the 
majority of N-RAS














































several markers of oncogene-driven senescence, namely 
cell flattening, increase in cellular size, significantly 
reduced Ki67 expression, increased SA-ß-Gal activity 
and the formation of SAHF (Figure 1A). As expected 
these foci were enriched for histone H3 methylated at 
lysine 9 (H3K9Me), a common marker of hetero-
chromatin [24] (Figure 1B). In contrast, melanocytes 
accumulating the co-expressed Copepod GFP (copGFP) 
did not arrest, showed no evidence of chromatin 
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Q61K induced melanocyte senescence was also 
associated with activation of the MAPK and AKT 
pathways, as shown by the increased phosphorylation of 
ERK (p-ERK), and AKT (p-AKT) at 5, 10 (data not 
shown) and 15 days post infection (Figure 1C). In 
addition, expression of oncogenic N-RAS led to p53 
induction, increased expression of the p16
INK4a and 
p21
Waf1 cyclin dependent kinase inhibitors and reduced 
accumulation of pRb phosphorylated at serine residues -














































induced p14ARF was not detectable by Western blot 
analysis [34]. Oncogenic N-RAS also induced a robust 
DNA damage response in melanocytes that was associa-
ted with the accumulation of senescence-associated DNA 
damage foci, which contain phosphorylated histone 
H2AX (γ-H2AX) and are not equivalent to SAHF [15] 
(Figure 2A). Further, there was a marked increase in the 
phosphorylation of CHK2 on Thr-68 (p-CHK2) and 
increased p53 phosphorylation on Ser-15 (p-p53), two 













































































































To examine the contribution of the DNA damage 
response to RAS-induced melanocyte senescence we 
suppressed ATM and ATR kinase activity with the 
addition of 4mM caffeine for 15 days. As expected, in 
the presence of N-RAS
Q61K, the addition of caffeine 
markedly inhibited phosphorylation of the ATM targets 
CHK2 and p53 (Figures 2B, 2C). Nevertheless, 
suppression of the DNA damage response had no 
detectable impact on the N-RAS induced melanocyte 
senescence program. In particular, melanocytes 
accumulating N-RAS
Q61K, regardless of exposure to 
caffeine, underwent potent cell cycle arrest (reduced 
Ki67 staining) that was associated with increased SA-ß-
Gal activity an the appearance of SAHF (Figure 2D). In 
addition, inhibition of the DNA damage checkpoint 
response did not impact on the N-RAS
Q61K-mediated 
induction of total p53, p21
Waf1, p16
INK4a and 
hypophosphorylated pRb (Figure 2B).  
 
Considering that the p53 pathway remained active 
(increased p53 and p21
Waf1 expression; see Figure 2B) 
in N-RAS
Q61K-expressing melanocytes with a dimin-
ished DNA damage response, we examined whether 
oncogene-induced senescence of human melanocytes 
required the p53 protein. To silence p53 expression we 
utilised lentiviral shRNA vectors that specifically target 
p53 and to minimise confounding effects of shRNA off-
target silencing two independent p53 silencing 
molecules were generated (Supplementary Figure 1). 
HEM1455 melanocytes were transduced with these 
shRNA molecules and three days post-infection the 
cells were re-transduced with lentiviral vectors 
expressing N-RAS
Q61K or copGFP. In all experiments 
we also applied a negative control shRNA molecule 
without homology to any human gene. 
 
The inhibition of p53 expression did not alter the cell 
cycle arrest induced by oncogenic N-RAS
Q61K (15 days 
after infection only 5% of N-RAS
Q61K melanocytes 
showed positive Ki67 staining regardless of p53 
expression and this can be compared to 23% Ki67 
positive p53-null melanocytes infected with the copGFP 
control; Figure 3A). Similarly, cellular senescence was 
initiated and maintained in the presence or absence of 
p53 expression; increased SA-ß-Gal activity appeared in 
48% of p53-null cells compared to 38% in the p53-
positive control cells, 15 days post transduction (Figure 
3A) and the two different p53-specific shRNAs exerted 
similar effects (data not shown). In fact no markers of 
senescence, including cell morphology, SA-ß-Gal 
activity, appearance of SAHF or Ki67 incorporation 
discriminated between p53-intact and p53-null 
senescent melanocytes. It is important to note, however, 
that p21
Waf1 expression was not induced by oncogenic 
N-RAS in p53-deficient melanocytes (Figure 3B). 
Figure  2.  Oncogenic  N‐RAS
Q61K  induces  DNA  damage
response in human melanocytes. (D) Human melanocytes
were  transduced  with  lentiviruses  expressing  N‐RAS
Q61K  or
copGFP and cultured for 15 days in presence (+) or absence (‐) of
4mM  caffeine.  The  efficiency  of  transduction  was  controlled
with the co‐expression of copGFP and was consistently above
90%.  Cell  proliferation  (Ki67),  chromatin  condensation  (DAPI),
and the appearance of increased SA‐ß‐Gal activity were analyzed
and  quantitated  15  days  after  infection.  Percentage  of  cells
positive for the indicated marker is shown in histograms, which





In p53-null N-RAS melanocytes the induction of 
p16
INK4a and hypophosphorylation of pRb was main-
tained (Figure 3B), and it seemed likely that the 
activation of pRb was dominant and sufficient to 
establish melanocyte senescence. Certainly silencing 
expression of both p53 and pRb bypassed N-RAS 
induced cell cycle arrest and senescence in this cell type 
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Q61K 
melanocytes showed positive Ki67 staining, compared to 
24% of N-RAS
Q61K melanocytes lacking both p53 and 
pRb and 23% of melanocytes expressing only control 
shRNA/copGFP; Figure 3A). To examine the individual 
role of pRb, HEM1455 melanocytes were transduced 
with a pRb-specific shRNA molecule and three days 
post-infection the cells were re-transduced with lentiviral 
vectors expressing N-RAS
Q61K or copGFP. pRb-null 














































ed onset of cell cycle arrest and senescence. In particular, 
10 days post infection with oncogenic N-RAS, 16% of 
pRb-null melanocytes remained positive for the 
proliferation marker Ki67 compared to only 5% of the 
pRb-positive melanocytes. Similarly, SA-ß-Gal activity 
was detected in only 19% of pRb-deficient N-RAS
Q61K 
melanocytes compared to 35% in the pRb-positive N-
RAS
Q61K cells. Further, the percentage of N-RAS
Q61K 
expressing cells with SAHF was clearly reduced, and 














































Figure  3.  Relative  contributions  of  the  p53  and  pRb  tumour  suppressor  pathways  in  N‐RAS
Q61K‐induced
melanocyte senescence. (A) Melanocytes were transduced with lentiviruses containing the indicated shRNA constructs.
Three  days  post  infection  the  cells  were  re‐transduced  with  lentiviruses  expressing  N‐RAS
Q61K  or  copGFP,  as  shown.
Representative examples at 15days after infection are shown. Cell proliferation (Ki67), chromatin condensation (DAPI), and
































These data suggest that the activation of pRb is the 
dominant effector of oncogene-induced melanocyte 
senescence, and thus upstream regulators of pRb 
function may represent critical melanoma tumour 
suppressors. For instance, loss of the melanoma 
predisposition gene p16
INK4a, detectably weakened the 
pRb-pathway and the senescence program in 
melanocytes by inhibiting the pRb-dependent 
development of SAHF [34]. Considering that the CDK 
inhibitors p16
INK4a and p21
Waf1 were both potently 
induced in melanocytes in response to N-RAS
Q61K 
expression (see Figure 1C), we wanted to establish 
whether the function of p16
INK4a in the formation of 
SAHF was specific to this CDK inhibitor or whether 
another senescence-associated CDK inhibitor p21
Waf1 
was equivalent in activity. The role of p21
Waf1 was 
examined utilising two, highly effective p21
Waf1-
specific lentiviral shRNA vectors (Supplementary 
Figure 1). HEM1455 melanocytes were transduced with 
these shRNA molecules and three days post-infection 
the cells were re-transduced with lentiviral vectors 
expressing N-RAS
Q61K or copGFP. In all experiments 
we also applied a negative control shRNA molecule 
without homology to any human gene.  
 
Depletion of p21
Waf1 did not detectably alter N-RAS 
induced cell cycle arrest or senescence in human 
melanocytes. The p21






































ded to oncogenic N-RAS by accumulating hypo-
phosphorylated pRb, p16
INK4a and p53 (Figure 3B), they 
enlarged, acquired increased SA-ß-Gal activity and 
were negative for the proliferation marker Ki67 (Figure 
3A). Unlike pRb-null melanocytes, there was no detect-
able delay in N-RAS induced arrest and senescence in 
p21
Waf1-deficient melanocytes. Importantly, in the 
absence of the p21
Waf1 CDK inhibitor, the formation of 
SAHF was not altered 10 and 15-post transduction 
(29% foci in p21
Waf1-null, vs 11% foci in pRb-null vs 
26% foci in shRNA control cells, 15 days post infection 
with N-RAS
Q61K; Figure 3A). The second p21
Waf1-spe-
cific shRNA exerted similar effects (data not shown).
 
 
To further investigate whether p16
INK4a was unique in 
promoting SAHF formation we developed a transient 
melanoma model to rapidly assess the functions of the 
p21
Waf1 and p16
INK4a. The functionally impaired 
p16
INK4a_R24P mutant that is unable to bind and inhibit 
CDK4 but retains CDK6 inhibitory activity was used as 
a control [34, 39]. The WMM1175 melanoma cells 
were transiently transfected with plasmids encoding 
each of these CDK inhibitors along with a plasmid 
encoding the enhanced green fluorescent protein 
(EGFP), which was used as a marker of transfection.  
The cell cycle proliferation, SAHF formation and SA-ß-
Gal activity of transfected WMM1175 cells was then 
assessed over 5-days. This was enough time to observe  
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the transiently transfected plasmids was still detectable. 
As expected, ectopic expression of wild-type p16
INK4a 
and p21
Waf1, but not p16
INK4a_R24P promoted rapid cell 
cycle arrest (Figure 4A). Similarly, p16
INK4a and p21
Waf1 


















































increased SA-ß-Gal activity by five days post transfec-
tion (Figure 4B). The only detectable difference between 
the two wild type CDK inhibitors was the induction of 
SAHF; only p16
INK4a accumulation led to the appearance 
of these distinctive foci, which were enriched for 
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The molecular mechanisms that trigger oncogene-
induced senescence have been studied extensively, and 
yet the relative contribution of the p16
INK4a/pRb and the 
p53/p21
Waf1 pathways in initiating and maintaining the 
senescence program remains poorly understood. In this 
study, we show that N-RAS
Q61K induces senescence in 
human melanocytes that was associated with markers of 
DNA damage response, and involved the activation of 
both the p53 and pRb pathways. Surprisingly neither the 
pharmacological inhibition of the DNA damage 
response pathway with caffeine nor silencing of p53 
expression had a detectable impact on the N-RAS
Q61K 
induced senescence of human melanocytes. In fact, no 
markers of senescence, including cell morphology, SA-
ß-Gal activity, appearance of SAHF or Ki67 incor-
poration discriminated between p53-intact and p53-null 
senescent melanocytes. Interestingly, caffeine 
diminished the phosphorylation of p53 on Ser-15, but 
did not reduce the overall levels of p53, or its activity 
(as measured by p21
Waf1  induction; Figure 2B) in 
melanocytes. Several other reports have also shown that 
inhibition of p53 phosphorylation at Ser-15 did not 
correlate with diminished p53 activity and this is 
indicative of p53 stabilization via multiple mechanisms 
[40, 41]. It is tempting to suggest that the melanoma 
tumour suppressor p14ARF is the critical activator of 
p53 in melanocytes. p14ARF stabilizes p53 by binding 
and inhibiting the p53 specific ubiquitin ligase, mdm2 
[42], rather than inducing p53 phosphorylation. We 
have previously shown however that p14ARF is only 
weakly induced by oncogenic N-RAS in human 
melanocytes, and is not required for p53 activation in 
response to N-RAS [34]. In fact, the ARF tumour 
suppressor appears to contribute to oncogene-induced 
senescence only in mouse cells (Table 1). 
 
It is reasonable to assume that in the absence of p53 the 
activated p16
INK4a/pRb pathway was sufficient to 
initiate and maintain senescence, and this appears to be 
the case in melanocytes. Not only did oncogenic N-
RAS potently induce p16
INK4a in melanocytes, pRb 
existed in its active hypophosphorylated form, and 
silencing of pRb significantly delayed the onset of 
senescence. Ultimately, the senescence program was 
activated in pRb-null melanocytes and this required the 
p53 pathway, as the simultaneous loss of p53 and pRb 
completely overcame N-RAS induce senescence in 
melanocytes. This is the first demonstration showing 
that melanocytes senesce in response to oncogenic 
signaling by engaging both the p53 and pRb pathways. 
 
It has been suggested that p53, p21
Waf1 and pRb act in a 
linear pathway, with p53-induced p21
Waf1 activating 
pRb to regulate cell entry into replicative senescence 
[43]. This model does not adequately account for the 
fact that pRb-null melanocytes ultimately senescence in 
response to oncogenic N-RAS. It is possible that the 
pRb homologues, p107 and p130 participate in 
oncogene-induced senescence as they can functionally 
compensate for pRb loss and, like pRb, are activated by 
p21
Waf1  and p16
INK4a [44]. Certainly, pRb-deficient 
MEFs senesce in culture, whereas MEFs with targeted 
deletion of all three pRb family members (pRb, p107 
and p130) do not [45]. Furthermore, p53 was capable of 
inducing senescence in pRb-null prostate cancer cells, 
but not in p107 and pRb depleted cells [46]. Although 
such compensation clearly exists, the fact that pRb 
mutations are common in human cancer, whereas p107 
and p130 mutations occur rarely [47], suggests that 
functional compensation for pRb loss must be context 
dependent. In the case of melanocytes, pRb (not p107 
and p130) is required for normal mouse melanocyte 
proliferation although arrest in response to growth 
factor deprivation was associated with the formation of 
pRb- and p130-transcription repressor complexes in 
human melanocytes (reviewed in [48]). We are cur-
rently exploring whether the response of human 
melanocytes to oncogenic signalling involves the pRb 
homologues, p107 and p130 and whether the 
contribution of p53 to melanocyte senescence is strictly 
dependent on the pRb family of proteins. 
 
Our data clearly demonstrate that oncogenic N-RAS 
acts primarily through the pRb pathway in melanocytes. 
Activation of this pathway involves both p21
Waf1 and 
p16
INK4a, and these were the only CDK inhibitors 
potently induced by oncogenic N-RAS in melanocytes 
(data not shown). We confirm that both p16
INK4a and 
p21
Waf1 can induce senescence, but their activities are 
clearly distinct. p16
INK4a expression promoted the 
formation of DAPI-stained heterochromatin foci that 
were enriched for the H3K9Me marker of SAHF. In 
contrast, ectopic p21
Waf1 expression had no detectable 
impact on chromatin structure even though cells were 
clearly arrested. Similarly, loss of p16
INK4a reduced the 
formation of SAHF in melanocytes [34], whereas loss 
of p21
Waf1, either via direct silencing or by silencing 
p53, had no detectable effect on SAHF formation. 
Although both p16
INK4a and p21
Waf1 can activate pRb 
their actions are not equivalent. p16
INK4a is a potent 
inhibitor of the cyclin D-dependent kinases, CDK4 and 
CDK6, whereas p21
Waf1 is sequestered by and acts as a 
positive regulator of these kinases. This pool of tethered 
p21
Waf1 is released as p16
INK4a accumulates and p21
Waf1 
redistributes to bind and inhibit cyclin E-CDK2 
complexes and induce G1 arrest [49]. The ability of 
p16
INK4a to inhibit the cyclin D-dependent kinases also 
enables it to block the assembly of DNA replication 
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replication, a function not shared by p21
Waf1 [50]. Thus, 
in melanocytes with oncogenic signalling only p16
INK4a 
can fully engage the pRb pathway to alter chromatin 
structure and silence the genes that are required for 
proliferation. Melanocytes undergoing replicative 
senescence also rely on the p16
INK4a/pRb axis, as p53 
and p21
Waf1 levels remain low in these arrested 
melanocytes [27]. We suggest that inhibition of cyclin 
D-dependent kinases and induction by senescence-
causing stimuli necessitate p16
INK4a inactivation in 
human cancers and distinguish this CDK inhibitor as a 
tumour suppressor.  
 
 
MATERIALS AND METHODS 
 
Cell culture and transfections. Human WMM1175 
melanoma cells (ARF-null, p53-null, pRb+/+; [51]) and 
U20S osteosarcoma cells were grown in Dulbecco’s 
modified Eagle’s medium (DMEM, Gibco BRL, 
Carlsbad, CA, USA) supplemented with 10% foetal 
bovine serum and glutamine. Human epidermal 
melanocytes (HEMs) were obtained from Cell 
Applications (Cell Applications, San Diego, CA, USA) 
and grown in HAM’s F10 media (Sigma, St. Louis. 
MO, USA), supplemented with ITS premix (Becton 
Dickinson, Franklin Lakes, NJ, USA), TPA, IBMX, 
cholera toxin, 20% fetal bovine serum and glutamine 
(modified from [52]). All cells were cultured in a 37°C 
incubator with 5% CO2. Caffeine (Sigma) was used at 






WMM1175 cells (1 × 10
5) were seeded on coverslips in 





100ng  pEGFPN1  (Clontech, Mountain View, CA, 
USA), as a transfection marker, using Lipofectamine 
2000 (Invitrogen, Carlsbad, CA, USA). 
 
Lentivirus transductions. Lentiviruses were produced in 
HEK293T cells using the pSIH1-H1-copGFP (Copepod 
green fluorescent protein) shRNA expression vector or 
the  pCDH-CMV-MCS-EF1-copGFP lentiviral vector 
(Systems Biosciences, Mountain View, CA, USA) 
encased in viral capsid encoded by three packaging 
plasmids as described previously [53]. Viruses were 
concentrated as described previously [54]. Viral titres 
were determined using 1 x 10
5 U2OS cells/well in six-
well plates, transduced with serial dilutions of the 
concentrated viral stocks in the presence of Polybrene 
(8 µg/ml; Sigma). Cells were harvested 48 h post-
transduction, analysed by flow cytometry for GFP 
expression and viral titre calculated. Cells were 
infecting using an MOI of 5-10 to provide infection 
efficiency above 90%.  
 
Constructs. The N-RAS lentiviral construct and p16
INK4a 
plasmids have been described elsewhere [33, 55]. The 
p21
Waf1 cDNA was kindly provided by Dr B. Vogelstein 
and subcloned into the pFLAG-CMV5b mammalian 
expression vector (Sigma). The p53-directed shRNA 
sequences correspond to nucleotides 956-974 and 1026-
1044 [56, 57] (Genbank accession number 
NM_000546). The p21
Waf1-directed shRNA sequences 
correspond to nucleotides 560-578 and 569-587 
(Genebank accession number NM_078467) [58]. The 
shRNA sequence targeting pRb corresponded to 
nucleotides 662-680  (Genebank accession number 
NM_000321.1) [59]. The non-silencing negative control 
shRNA did not show complete homology to any known 
human transcript and had the following sequence: 5’-
TTAGAGGCGAGCAAGACTA-3’.  
 
Western Blotting. Total cellular proteins were extracted 
at 4°C using RIPA lysis buffer containing protease 
inhibitors (Roche, Basel, Switzerland). Proteins (30-
50µg) were resolved on 12% SDS-polyacrylamide gels 
and transferred to Immobilon-P membranes (Millipore, 
Bedford, MA, USA). Western blots were probed with 
antibodies against p16
INK4a (N20, Santa Cruz, CA, 
USA), p21
Waf1 (C-19, Santa Cruz), ß-actin (AC-74, 
Sigma-Aldrich), p53 (DO-1, Santa Cruz), p-p53 (#9284, 
Cell Signalling, Danvers, MA, USA), p-ERK (E4, Santa 
Cruz), ERK (137F5, Cell Signalling), p-AKT (L32A4, 
Cell Signalling), AKT (11E7, Cell Signalling), c-MYC 
(A14, Santa Cruz), H3K9Me (Millipore) and 
phosphorylated p-pRb (#9308, Cell Signalling). 
 
Indirect immunofluorescence. Cultured cells (3-4 x 10
4) 
seeded on coverslips in 12-well plates were washed in 
PBS and fixed in 2% formaldehyde, 0.2% gluta-
raldehyde, 7.4 mM Na2HPO4, 1.47 mM KH2PO4, 137 
mM NaCl, and 2.68 mM KCl. Cells were then rinsed 
three times with PBS and SA-ß-Gal activity was 
detected as previously described [60]. Cells fixed in 
3.7% formaldehyde were immunostained for 50 min 
with primary antibody followed by a 50 min exposure 
to Alexa Fluor 594-conjugated secondary IgG   
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